IMPORTANT SAFETY INFORMATION  Prescribing Information

Indication: LEXIVA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The PI-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent. Once-daily administration of LEXIVA/ritonavir is not recommended for adult PI-experienced patients or any pediatric patients.

Important Safety Information: LEXIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity to any of the components of this product or to amprenavir. LEXIVA is contraindicated with ergot derivatives, PROPULSID®*(cisapride), ORAP®* (pimozide), VERSED®* (midazolam), HALCION®*(triazolam), rifampin, MEVACOR®* (lovastatin), ZOCOR®* (simvastatin),RESCRIPTOR®* (delavirdine), or St. John’s wort (Hypericum perforatum). If LEXIVA is coadministered with ritonavir, TAMBOCOR®* (flecainide) and RYTHMOL®* (propafenone) are also contraindicated. CONTINUED BELOW

Resources

ViiV Healthcare offers the following resources to help you stay informed about its products and its commitment to HIV research and care:

  • Patient education: Downloadable educational brochures for patients about LEXIVA, in both English and Spanish
  • Support card: Learn more about ViiV Healthcare's program to help eligible patients pay for LEXIVA
  • ViiV Healthcare's commitment: Details on ViiV Healthcare and GlaxoSmithKline's global community outreach efforts to battle HIV in the developing world
  • ViiV for You: Information on ViiV Healthcare's program (currently administered by GSK) that help people who can't afford the medicines they need
  • Useful links: A list of helpful Web sites offering a breadth of information about HIV, its treatment, and living with the condition

Important Safety Information

Indication

LEXIVA is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.

Important Safety Information

Other Drug Interactions

Resistance

Dosing | Data on LEXIVA | Healthcare providers’ tool kit | Resources | Risk & Side Effects